NCT02292043

Brief Summary

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2013

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

October 31, 2014

Completed
17 days until next milestone

First Posted

Study publicly available on registry

November 17, 2014

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

November 17, 2014

Status Verified

November 1, 2014

Enrollment Period

1.7 years

First QC Date

October 31, 2014

Last Update Submit

November 12, 2014

Conditions

Congestive Heart Failure

Outcome Measures

Primary Outcomes (1)

  • Morbidity

    1 months to 3 months after discharge

Secondary Outcomes (1)

  • The decreased degree of NT-proBNP higher than 30%

    3 months after discharge

Study Arms (2)

idiopathic dilated cardiomyopathy group

idiopathic dilated cardiomyopathy group treated with HTEA

Drug: HTEA

post-myocardial infarction group

post-myocardial infarction group treated with TEA

Drug: HTEA

Interventions

HTEADRUG

HTEA

idiopathic dilated cardiomyopathy grouppost-myocardial infarction group

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

heart failure.

You may qualify if:

  • chronic cardiac failure patients in our hospital were selected and divided into two groups.

You may not qualify if:

  • Vavular diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ren Xiaohui

Harbin, Heilongjiang, 150001, China

RECRUITING

the first affiliated hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China

RECRUITING

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • wei liu

    First Affiliated Hospital of Harbin Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

wei liu, Ph.D.

CONTACT

86-18904502999

xiaohui ren

CONTACT

86-451-85552320

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Liu

Study Record Dates

First Submitted

October 31, 2014

First Posted

November 17, 2014

Study Start

May 1, 2013

Primary Completion

January 1, 2015

Study Completion

January 1, 2015

Last Updated

November 17, 2014

Record last verified: 2014-11

Locations

CN(2)